I wrote about the work at Rejuvenate Bio and Oisin Biotechnology to reverse aging or improve longevity. People do not want to get their hopes up for the life-extending aspects. A biotech miracle was already achieved although it has so far happened in mice and dogs.

Rejuvenate Bio and Oisin Biotechnology have both indicated that they are successfully introducing genetic modifications to most of the cells of an adult organism with an injection. This change and delivery mechanism is not being blocked by the immune system.

Oisin Biotechnology is using Lipid-based delivery systems.

Oisin Biotech is safely delivering over 15 milligrams per kilogram of DNA plasmids encased in lipids. This is introduced in an injection. Each animal received a single dose. No antibody response in immune-competent mice, even at high doses.

Lipid nanoparticles are an established platform for in vivo drug delivery
• Improved protection
• Improved pharmacodynamics, biodistribution
• Tunable circulation time and targeting

Intracellular delivery is dependent upon cationic lipids
• Neutral liposomes (NL) have no charge, but are relatively poor at intracellular delivery
• Cationic liposomes (CL) have strong positive charge and deliver efficiently, but are highly toxic

They are introducing suicide genes into most of the cells of an adult mouse to trigger zombie senescent cells to die.

Oisin Biotech used single injections of LNP results in 75-90% reduction of prostate cancer tumor after 48 hours.

George Church’s Harvard plans to publish a scientific report on a technique that extends rodents’ lives by modifying two genes to act on four major diseases of aging: heart and kidney failure, obesity, and diabetes. According to Church, the results are “pretty eye-popping.”

Again the implication is that Rejuvenate Bio also have successful means to introduce genetic changes throughout the adult body of the mouse and probably in dogs.

Rejuvenate Bio has a pipeline of 60 genetic changes that they have identified as having the effect of reversing some aspect of aging.

Has Rejuvenate Bio identified all genetic aspects of aging? Probably not.

Could Rejuvenate Bio and Oisin Biotech and others introduce genetic modifications into adults to give most of the enhanced health and biology of supercentenarians (those who live over 110 years of age) and reverse major aspects of aging? It seems yes.

Could the techniques for in vivo genetic modifications be further improved and scaled up? This seems likely.

Can Artificial Intelligence and other technologies scale up the identification of genetic modification targets? This seems likely.

There are genetic targets already for myostatin inhibition (several times more powerful that steroids for muscle growth).

There are genetic targets for unusually strong bones.

There are targets for enhancing intelligence. This seems to require thousands of genetic modifications.

There are roughly 10,000 monogenic or single-gene diseases. Only 5% are treatable today. Ark Investment Management believes treating these diseases are worth an annual $70 billion globally. Other areas of interest include stem cell therapy research, personalized medicine, drug development, agriculture, biofuels, and more. The successful treatment of those diseases will provide huge revenues to the biotech companies who will also be pursuing antiaging and transhumanist modifications.

Whole body genetic modification has the potential to have similar cost profiles and the effectiveness of vaccination.